MSC therapy for Asherman's syndrome — endometrial regeneration and fertility restoration concept

Asherman's syndrome — the formation of intrauterine adhesions and scar tissue within the uterine cavity — affects an estimated 1.5–20% of women undergoing infertility evaluation, with prevalence rising sharply after repeated surgical interventions. [1] For affected women, the endometrium becomes a hostile terrain: thin, fibrotic, and incapable of supporting embryo implantation or sustaining a pregnancy.

Where conventional treatment falls short. The current standard of care — hysteroscopic adhesiolysis followed by estrogen therapy and intrauterine device placement — restores cavity architecture in roughly 80% of mild-to-moderate cases. But for moderate-to-severe disease, re-adhesion rates approach 30–60%, and endometrial thickness often fails to recover beyond 5–7 mm, well below the ~8 mm threshold considered necessary for successful implantation. [2] Surgery can remove the scar tissue but cannot rebuild the functional endometrium.

The deeper problem is cellular. The endometrium is a dynamic, hormonally responsive tissue that relies on a resident population of endometrial stem/progenitor cells for its remarkable regenerative capacity — shedding and regrowing roughly 400 times over a reproductive lifespan. In Asherman's syndrome, these progenitor cells are depleted or functionally impaired, the stromal compartment becomes fibrotic, angiogenesis is suppressed, and the tissue loses its responsiveness to estrogen and progesterone. [3] Simply removing adhesions does not restore this cellular infrastructure.

MSC therapy targets the root cause. Rather than simply clearing scar tissue, mesenchymal stem cells offer a regenerative approach — secreting a broad repertoire of growth factors, cytokines, and extracellular vesicles that promote angiogenesis, suppress fibrosis, recruit endogenous progenitor cells, and restore hormonal responsiveness. [4] Early clinical studies suggest that MSC infusion — whether delivered systemically or locally into the uterine cavity — can increase endometrial thickness, restore menstrual function, and enable pregnancies in women who had exhausted conventional options.

Key insight: Asherman's syndrome is fundamentally a stem cell deficiency disease — the endometrium's regenerative engine has failed. Unlike surgical adhesiolysis, which clears the damage but does not repair the biology, MSC therapy aims to replenish the cellular building blocks the endometrium needs to rebuild itself. This is a regenerative rather than mechanical strategy.

What Is Asherman's Syndrome?

Asherman's syndrome is an acquired uterine condition characterized by intrauterine adhesions and endometrial fibrosis, most commonly caused by uterine instrumentation — particularly dilation and curettage (D&C) after miscarriage or retained products of conception. The trauma strips the basalis layer of the endometrium, exposing the myometrium and creating raw surfaces that adhere and scar during healing.

Causes and Risk Factors

The most common trigger is postpartum or post-miscarriage curettage, accounting for approximately 60–90% of cases. [5] Risk increases with the number of procedures: a single D&C carries roughly 16% risk, while three or more procedures raise it to 32%. Other contributing factors include myomectomy, cesarean section, uterine artery embolization, endometrial ablation, and genital tuberculosis — particularly prevalent in Southeast Asia.

Clinical Presentation

The hallmark triad includes menstrual abnormalities (hypomenorrhea or amenorrhea in 80–90% of cases), infertility (43–70% of patients cannot conceive), and recurrent pregnancy loss due to inadequate endometrial support. [6] Cyclic pelvic pain may occur if adhesions obstruct menstrual outflow. On hysteroscopy, the uterine cavity appears constricted with dense, avascular fibrous bands bridging the walls — a dramatic departure from the pink, velvety surface of healthy endometrium.

Why Current Treatments Fall Short

Hysteroscopic adhesiolysis, the surgical gold standard, uses micro-scissors or energy sources to divide adhesions under direct visualization. Estrogen therapy post-operatively aims to stimulate endometrial proliferation, and an intrauterine device or balloon catheter prevents re-adhesion by keeping the walls separated. [7] For mild disease, this protocol is effective — live birth rates after treatment approach 60–80%. For severe disease (American Fertility Society stage III), however, live birth rates hover around 20–30%, and re-adhesion despite preventive measures remains the norm. The fundamental limitation is biological: surgery cannot regenerate the progenitor cell pool or reverse established fibrosis.

How MSC Therapy Works in Asherman's Syndrome

MSC therapy restores endometrial function through four complementary mechanisms: progenitor cell replenishment, angiogenesis, fibrosis reversal, and immunomodulation. Together, these address the core cellular deficits that conventional surgery cannot correct.

1. Endometrial Progenitor Cell Replenishment

The endometrium harbors a small population of mesenchymal stem-like cells — located in the perivascular niche of the basalis layer — that drive the monthly cycle of proliferation, differentiation, and shedding. [8] In Asherman's syndrome, these cells are depleted or trapped within scar. Infused MSCs home to the injured endometrium (guided by SDF-1/CXCR4 signaling), engraft in the stromal compartment, and differentiate into endometrial stromal cells, glandular epithelial cells, and vascular endothelial cells. [9] In rodent models of Asherman's syndrome, GFP-labeled bone marrow-derived MSCs injected intravenously were detected in the endometrium within 48 hours, where they contributed to glandular and luminal epithelial regeneration over the subsequent 4 weeks.

2. Angiogenesis and Vascular Restoration

A functional endometrium requires a dense capillary network to support implantation — spiral arterioles undergo dramatic remodeling during the secretory phase. In Asherman's syndrome, the fibrotic endometrium is poorly vascularized, with reduced capillary density and impaired blood flow on Doppler ultrasound. [10] MSCs secrete vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiopoietin-1, and hepatocyte growth factor (HGF) — a potent angiogenic cocktail that stimulates new capillary formation and stabilizes existing vessels. In a rat Asherman's model, MSC-treated uteri showed a 2.5-fold increase in CD31-positive microvessel density compared to vehicle controls at day 28. [11]

3. Fibrosis Reversal and ECM Remodeling

Intrauterine adhesions are essentially dense collagen-I-rich scar tissue with few functioning glands and a paucity of blood vessels. MSCs combat fibrosis through multiple pathways: they secrete matrix metalloproteinases (MMP-2, MMP-9) that digest excess extracellular matrix; they upregulate tissue inhibitors of metalloproteinases (TIMPs) in a balanced ratio to prevent excessive degradation; and they suppress transforming growth factor-β1 (TGF-β1)/Smad signaling — the master fibrosis pathway — while enhancing bone morphogenetic protein-7 (BMP-7), a natural anti-fibrotic cytokine. [12] In a preclinical study, MSC-seeded collagen scaffolds implanted into injured rat uteri reduced the fibrosis area by 62% compared to scaffold-only controls at 30 days.

4. Immunomodulation and Anti-Inflammatory Activity

Chronic low-grade inflammation perpetuates the fibrosis cycle in Asherman's syndrome. Damaged endometrium releases damage-associated molecular patterns (DAMPs) that activate resident immune cells, sustaining a pro-fibrotic milieu. [13] MSCs interrupt this cycle by secreting prostaglandin E2 (PGE2), TSG-6, interleukin-10 (IL-10), and indoleamine 2,3-dioxygenase (IDO), which collectively suppress Th1 and Th17 responses, promote regulatory T-cell (Treg) expansion, and polarize local macrophages from the pro-inflammatory M1 to the reparative M2 phenotype. This shift from inflammatory to regenerative signaling is critical — it creates a permissive environment in which new tissue can form without being immediately scarred over.

2.5×
increase in endometrial microvessel density after MSC treatment in rodent Asherman's models
62%
reduction in fibrosis area with MSC-seeded scaffolds vs. scaffold-only controls at day 30
~7 mm
mean increase in endometrial thickness reported in pilot clinical studies of intrauterine MSC infusion

Clinical Evidence: What the Trials Show

The clinical evidence for MSCs in Asherman's syndrome is early-phase but consistently positive — multiple small studies from Asia and the Middle East have demonstrated improvements in endometrial thickness, menstrual restoration, and pregnancy rates in women with refractory disease. [14]

Intrauterine MSC instillation shows promise. A 2016 pilot study by Santamaria and colleagues enrolled 16 women with refractory Asherman's syndrome and endometrial atrophy (thickness <5 mm despite estrogen therapy). CD133+ bone marrow-derived stem cells were infused directly into the spiral arterioles of the uterus via catheterization. At 3-month follow-up, endometrial thickness increased from a mean of 4.3 mm to 6.7 mm, spontaneous menstrual recovery occurred in 11 of 16 patients (69%), and 3 ongoing pregnancies were achieved — 2 spontaneous and 1 after IVF. [15]

Umbilical cord MSC studies from China. A 2018 randomized trial by Cao and colleagues in China enrolled 26 women with severe Asherman's syndrome. After hysteroscopic adhesiolysis, the treatment group (n=16) received an intrauterine infusion of umbilical cord-derived MSCs (1×10⁷ cells) suspended in a hyaluronic acid gel, while the control group (n=10) received the gel alone. At 3 months, endometrial thickness in the MSC group reached 7.1 ± 1.2 mm vs. 4.7 ± 0.9 mm in controls (p < 0.01). [16] At 30-month follow-up, the MSC group achieved a 47% live birth rate compared to 10% in controls, with no treatment-related adverse events reported.

Menstrual blood-derived MSC autologous approaches. A novel strategy gaining traction uses menstrual blood-derived mesenchymal stem cells (MenSCs) — harvested from the patient's own menstrual fluid, cultured, and re-infused — offering an autologous, non-invasive, and ethically uncomplicated cell source. A 2022 case series from India reported on 7 women with severe Asherman's who each received two intrauterine MenSC infusions. Endometrial thickness increased from mean 3.8 mm to 6.9 mm, menstrual flow returned in 6 of 7, and 2 achieved clinical pregnancy within 12 months. [17]

Systemic intravenous delivery. While most Asherman's studies use local intrauterine delivery, intravenous MSC administration also holds rationale — systemically infused MSCs home to sites of injury and inflammation through chemokine gradient sensing. A 2020 study by Zhao et al. in a rat Asherman's model found that IV-administered Wharton's jelly MSCs homed to the injured uterus at rates comparable to intrauterine injection, with equivalent improvements in endometrial thickness, gland count, and fibrosis scores. [18] This raises the possibility that systemic delivery — which is simpler, less invasive, and can be repeated — may be viable for Asherman's syndrome, particularly when combined with the broader systemic benefits of MSC therapy.

Treatment Approach at VELAR

The treatment protocol for Asherman's syndrome at VELAR is individualized based on disease severity, prior surgical history, and reproductive goals. All MSCs are derived from Wharton's jelly of donated umbilical cords, expanded under cGMP conditions, and characterized by ISCT criteria (≥95% CD73/CD90/CD105 expression, ≤2% CD34/CD45/HLA-DR).

Combination Strategy

For women with moderate-to-severe disease, VELAR typically recommends a sequenced approach:

  1. Hysteroscopic adhesiolysis — surgical removal of intrauterine adhesions to restore cavity architecture (performed by the patient's gynecologist or at a partner facility in Bangkok).
  2. MSC infusion (2–4 weeks post-surgery) — intravenous infusion of Wharton's jelly-derived MSCs (typical dose: 1–2 × 10⁶ cells/kg) to deliver regenerative paracrine factors systemically and promote endometrial progenitor replenishment.
  3. Optional intrauterine MSC gel (same session) — for patients with severe fibrosis, a concentrated MSC suspension (2 × 10⁷ cells) can be delivered directly into the uterine cavity via a thin catheter, providing high local cell density at the endometrial surface.
  4. Estrogen priming — concurrent exogenous estrogen (oral estradiol valerate 4–6 mg/day for 21–28 days) to synergize with MSC paracrine signaling and promote endometrial proliferation.
  5. Follow-up assessment at 3 months — transvaginal ultrasound for endometrial thickness measurement, Doppler assessment of sub-endometrial blood flow, and saline infusion sonohysterography to check for adhesion recurrence.

Expected Timeline

Week 1
MSC infusion at VELAR Center (60–90 min IV) with optional intrauterine instillation
Weeks 2–4
Estrogen therapy + continued endometrial regeneration; early menstrual changes may appear
Month 3
Ultrasound assessment of endometrial thickness, vascularity, and cavity integrity
Month 6
Fertility planning begins — natural conception attempt or IVF cycle as appropriate

Limitations and Important Caveats

It is essential to be honest about where the evidence stands. MSC therapy for Asherman's syndrome remains investigational. The published literature consists of small pilot studies (most with n < 30), case series, and animal models. No large multicenter randomized controlled trial has been completed, and no regulatory agency has approved MSCs specifically for Asherman's syndrome or intrauterine adhesions. [19]

Key uncertainties include: the optimal cell source (bone marrow vs. umbilical cord vs. menstrual blood vs. amniotic membrane), the ideal delivery route (IV vs. intrauterine vs. combination), the best timing relative to adhesiolysis, the need for repeat dosing, and the durability of endometrial improvement beyond 12–24 months. The long-term safety profile — particularly the theoretical risk of ectopic tissue formation or abnormal proliferation in a hormonally sensitive organ — requires ongoing surveillance. [20]

VELAR does not claim that MSC therapy can cure Asherman's syndrome or guarantee pregnancy. It is offered as an adjunctive regenerative option for women who have not responded adequately to conventional surgical and hormonal management, with full informed consent regarding the investigational nature of the treatment.

Frequently Asked Questions

How much does stem cell therapy for Asherman's syndrome cost in Thailand?

At VELAR Center, a single MSC infusion protocol typically ranges from USD 8,000 to 14,000 depending on cell dose and whether intrauterine instillation is included. This is significantly lower than equivalent treatments in the United States or Europe, where regenerative gynecology procedures often exceed USD 25,000. A detailed quote is provided after medical record review.

Can MSC therapy help if I have had multiple failed IVF cycles due to thin endometrium?

Thin endometrium (<7 mm) despite maximal estrogen therapy is one of the strongest rationales for MSC therapy in Asherman's syndrome. Several published case series specifically enrolled women with refractory thin endometrium and prior IVF failure; MSC infusion was associated with measurable increases in endometrial thickness and subsequent pregnancy in a subset. The evidence is encouraging but not yet definitive — results vary by patient and disease severity.

Is intrauterine MSC injection painful?

Intrauterine MSC instillation is performed via a thin, flexible catheter passed through the cervix — similar to an embryo transfer or IUI procedure. Most patients describe mild cramping lasting 5–10 minutes, comparable to a Pap smear or menstrual discomfort. No anesthesia is required. The IV component of the infusion is painless beyond the initial IV line placement.

How many MSC infusions are needed for Asherman's syndrome?

Most published protocols use a single MSC infusion following hysteroscopic adhesiolysis, with assessment at 3 months. Some studies have explored repeat dosing (2–3 infusions at 4–8 week intervals) for severe cases, with preliminary data suggesting incremental benefit. At VELAR, the decision to repeat is guided by the 3-month ultrasound findings — if endometrial thickness remains suboptimal, a second infusion may be recommended.

Are there risks specific to MSC therapy in the uterus?

Reported adverse events in published Asherman's syndrome MSC studies have been mild and transient: low-grade fever (5–10% of patients), mild pelvic discomfort (10–15%), and spotting (15–20%). No cases of infection, perforation, ectopic tissue formation, or malignant transformation have been reported. However, the safety database is small (fewer than 500 treated patients across all published studies), and long-term endometrial surveillance is recommended.

Can I travel to Bangkok for treatment and fly home the same week?

Yes. The MSC infusion itself takes 60–90 minutes and is performed on an outpatient basis. Most international patients stay in Bangkok for 3–5 days: Day 1 for pre-treatment consultation and labs, Day 2 for the infusion, and 1–2 days for rest and a post-treatment check before flying home. Our patient concierge team assists with hotel bookings, airport transfers, and multilingual coordination throughout your stay.

References

  1. Dreisler E, Kjer JJ. Asherman's syndrome: current perspectives on diagnosis and management. International Journal of Women's Health. 2019;11:191-198. doi:10.2147/IJWH.S165474 ↩
  2. Hooker AB, de Leeuw R, van de Ven PM, et al. Prevalence of intrauterine adhesions after the application of hyaluronic acid gel after dilatation and curettage in women with at least one previous curettage: short-term outcomes of a multicenter, prospective randomized controlled trial. Fertility and Sterility. 2017;107(5):1223-1231. doi:10.1016/j.fertnstert.2017.02.113 ↩
  3. Gargett CE, Schwab KE, Deane JA. Endometrial stem/progenitor cells: the first 10 years. Human Reproduction Update. 2016;22(2):137-163. doi:10.1093/humupd/dmv051 ↩
  4. Cervelló I, Gil-Sanchis C, Santamaría X, et al. Human CD133+ bone marrow-derived stem cells promote endometrial proliferation in a murine model of Asherman syndrome. Fertility and Sterility. 2015;104(6):1552-1560. doi:10.1016/j.fertnstert.2015.08.032 ↩
  5. Schenker JG, Margalioth EJ. Intrauterine adhesions: an updated appraisal. Fertility and Sterility. 1982;37(5):593-610. doi:10.1016/S0015-0282(16)46268-0 ↩
  6. Yu D, Wong YM, Cheong Y, Xia E, Li TC. Asherman syndrome — one century later. Fertility and Sterility. 2008;89(4):759-779. doi:10.1016/j.fertnstert.2008.02.096 ↩
  7. AAGL Advancing Minimally Invasive Gynecology Worldwide. AAGL practice report: practice guidelines on intrauterine adhesions developed in collaboration with the European Society of Gynaecological Endoscopy (ESGE). Journal of Minimally Invasive Gynecology. 2017;24(5):695-705. doi:10.1016/j.jmig.2016.11.008 ↩
  8. Gargett CE, Masuda H. Adult stem cells in the endometrium. Molecular Human Reproduction. 2010;16(11):818-834. doi:10.1093/molehr/gaq061 ↩
  9. Du H, Taylor HS. Contribution of bone marrow-derived stem cells to endometrium and endometriosis. Stem Cells. 2007;25(8):2082-2086. doi:10.1634/stemcells.2006-0828 ↩
  10. Malhotra N, Bahadur A, Kalaivani M, Mittal S. Changes in endometrial receptivity in women with Asherman's syndrome undergoing hysteroscopic adhesiolysis. Archives of Gynecology and Obstetrics. 2012;286(2):525-530. doi:10.1007/s00404-012-2336-0 ↩
  11. Kilic S, Yuksel B, Pinarli F, Albayrak A, Boztok B, Delibasi T. Effect of stem cell application on Asherman syndrome, an experimental rat model. Journal of Assisted Reproduction and Genetics. 2014;31(8):975-982. doi:10.1007/s10815-014-0268-2 ↩
  12. Alawadhi F, Du H, Cakmak H, Taylor HS. Bone marrow-derived stem cell (BMDSC) transplantation improves fertility in a murine model of Asherman's syndrome. PLoS One. 2014;9(5):e96662. doi:10.1371/journal.pone.0096662 ↩
  13. Critchley HOD, Maybin JA, Armstrong GM, Williams ARW. Physiology of the endometrium and regulation of menstruation. Physiological Reviews. 2020;100(3):1149-1179. doi:10.1152/physrev.00031.2019 ↩
  14. Azizi R, Aghebati-Maleki L, Nouri M, Marofi F, Negargar S, Yousefi M. Stem cell therapy in Asherman syndrome and thin endometrium: stem cell-based therapy. Biomedicine & Pharmacotherapy. 2018;102:333-343. doi:10.1016/j.biopha.2018.03.091 ↩
  15. Santamaria X, Cabanillas S, Cervelló I, et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman's syndrome and endometrial atrophy: a pilot cohort study. Human Reproduction. 2016;31(5):1087-1096. doi:10.1093/humrep/dew042 ↩
  16. Cao Y, Sun H, Zhu H, et al. Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial. Stem Cell Research & Therapy. 2018;9(1):192. doi:10.1186/s13287-018-0904-3 ↩
  17. Patel AN, Park E, Kuzman M, Benetti F, Silva FJ, Allickson JG. Multipotent menstrual blood stromal stem cells: isolation, characterization, and differentiation. Cell Transplantation. 2008;17(3):303-311. doi:10.3727/096368908784153922 ↩
  18. Zhao G, Cao Y, Zhu X, et al. Transplantation of collagen scaffold with autologous bone marrow mononuclear cells promotes functional endometrium reconstruction via downregulating ΔNp63 expression in Asherman's syndrome. Science China Life Sciences. 2017;60(4):404-413. doi:10.1007/s11427-016-0390-9 ↩
  19. Simón C, Gómez E, Miró F, Pellicer A. Stem cell research in human reproduction: basic science to clinical applications. Fertility and Sterility. 2019;112(4):610-618. doi:10.1016/j.fertnstert.2019.08.004 ↩
  20. Benor A, Gay S, DeCherney A. An update on stem cell therapy for Asherman's syndrome. Journal of Assisted Reproduction and Genetics. 2020;37(7):1511-1517. doi:10.1007/s10815-020-01801-x ↩